Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 687 of 6351
-
Engineered immune cells take on lupus in early trial
Disease control Recruiting nowA Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Early phase 1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New sleepiness drug could change lives for narcolepsy and hypersomnia patients
Symptom relief Recruiting nowNarcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness \[EDS\]). People living with these conditions might find it hard to stay alert…
Phase 2 • Sponsor: Centessa Pharmaceuticals (UK) Limited • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
New hope for GVHD patients: ruxolitinib tested as First-Line therapy
Disease control Recruiting nowAllogeneic transplant is potentially curative for hematological malignancies but its use is limited by the development of GVHD. Ruxolitinib now has FDA approval for treatment of chronic GVHD that has failed 1-2 prior lines of therapy based on a prior large, randomized phase III s…
Phase 2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can stem cells boost brain surgery for epilepsy?
Disease control Stopped earlyThis study is a non-randomized, open label, phase 1 clinical trial to evaluate the fesibility and safety of intrathalamic delivery of MSCs during standard of care DBS surgery for epilepsy. Subjects will be screened at our outpatient clinic and interested qualified subjects will …
Early phase 1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New imaging agent could spot multiple cancers with one scan
Diagnosis Recruiting nowThis study aims to establish and optimize the trophoblast cell surface antigen 2 (Trop2)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging method and its physiological and pathological distribution characteristics, based on which the diagnost…
Phase 2/3 • Sponsor: RenJi Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
Hope for cancer patients: drug may shield ears from chemo damage
Prevention Recruiting nowThe purpose of this study is to evaluate the efficacy of N-acetylcysteine (NAC) in preventing cisplatin-induced ototoxicity in patients receiving cisplatin-based chemotherapy. Cisplatin is a highly effective chemotherapeutic agent but often leads to permanent hearing loss (ototox…
Phase 2 • Sponsor: Siriraj Hospital • Aim: Prevention
Last updated Jun 27, 2026 08:13 UTC
-
New triple therapy shows promise for tough lung cancer
Disease control Recruiting nowMulticenter, Phase II Randomized Controlled Study of Adebrelimab Combined with Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)
Phase 2 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New PET scan targets hidden cancers with precision
Diagnosis Recruiting nowThis study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging for diagnosing human malignancies, including renal cell carcinoma (particularly clear cell renal cell carcinoma), ly…
Phase 2 • Sponsor: RenJi Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:31 UTC
-
New ASL-Based therapy aims to tackle alcohol and trauma in deaf community
Disease control Recruiting nowThe U.S. Deaf community - a group of more than one million Americans who communicate using American Sign Language (ASL) - experiences nearly triple the rate of lifetime problem drinking and twice the rate of trauma exposure compared to the general population. Although there are s…
Sponsor: University of Massachusetts, Worcester • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Heating up tumors: could thermal therapy boost immune attack on breast cancer?
Disease control CompletedIn this study, breast cancer (BC) patients eligible for inclusion will be divided into two groups according to molecular typing and subtyping, which combined immunotherapy and multimodal thermal therapy with conventional neoadjuvant chemotherapy, to explore methods of immune indu…
Sponsor: Fudan University • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Brain bleed breakthrough? embolization procedure aims to stop repeat hematomas
Disease control Recruiting nowCOMPLEMENT study (ChrOnic subdural hematoMa Patients suppLemented with Embolization of Middle mENingeal artery Trial) is a prospective, open label, blinded endpoint (PROBE), Japanese, two-arm, randomized, controlled, post-market study to assess the efficacy and safety of middle m…
Sponsor: Kazutaka Uchida • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could a daily pill tame severe eczema in kids?
Disease control OngoingPediatric atopic dermatitis (AD), also known as childhood eczema, is a skin condition that may cause a rash and itching due to inflammation of the skin. The purpose of this study is to assess the change in disease activity (Efficacy) and to assess the safety of upadacitinib in co…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New hope for rare ovarian cancer? drug trial targets Hard-to-Treat clear cell tumors
Disease control Recruiting nowThe purpose of this research study is to see if the study drug Belzutifan is effective and safe for participants with clear cell gynecologic malignancy, including but not limited to, ovarian cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, or endometrio…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New HIV prevention shot could last 4 months
Prevention OngoingThis study will evaluate the pharmacokinetics (PK), safety, and tolerability of a new formulation of Cabotegravir (CAB) dosed every 4-months (Q4M) for pre-exposure prophylaxis (PrEP) in participants at risk of HIV-1 acquisition.
Phase 2 • Sponsor: ViiV Healthcare • Aim: Prevention
Last updated Jun 27, 2026 07:58 UTC
-
Blue light surgery may slash bladder cancer recurrence
Disease control Recruiting nowComparing white-light cystoscopy (WLC) and blue-light cystoscopy (BLC) in TURBT for high risk (HR) non-muscle invasive bladder cancer (NMIBC) patients is crucial to determine the most effective method for reducing residual disease burden and improving recurrence-free survival. En…
Phase 3 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Tailored drug strategy aims to keep myeloma in check after transplant
Disease control Recruiting nowThis study evaluates an individualized approach combining highly active maintenance treatment with elranatamab with peripheral blood-based clonotypic measurable residual disease (MRD) testing in patients with newly diagnosed multiple myeloma. The overall goal is to generate effic…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New combo therapy aims to boost immune attack on tough breast cancer
Disease control Recruiting nowThis study aims to explore the best combination patterns of radiotherapy and immunotherapy for advanced triple-negative breast cancer (TNBC).
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New cocktail aims to tame rare blood cancer
Disease control Recruiting nowThe purpose of this study is to determine the very good partial response (VGPR) or better rate in participants with Waldenström macroglobulinemia (WM). The names of the study drugs involved in this study are as follows: zanubrutinib, bendamustine, and rituximab.
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Hope for rare hunger disorder: new drug enters final testing phase
Symptom relief Stopped earlyThe goal of this clinical trial is to learn if ARD-101 works to treat hyperphagia-related behavior in patients with Prader-Willi syndrome (PWS). It will also teach us about the safety of ARD-101. The main questions it aims to answer are: * Does ARD-101 improve the total score o…
Phase 3 • Sponsor: Aardvark Therapeutics, Inc. • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Immune-Boosting drug could help fight High-Risk thyroid cancer before surgery
Disease control Recruiting nowThis window of opportunity trial is studying a checkpoint inhibitor agent to treat differentiated thyroid cancer in a neoadjuvant setting. A checkpoint inhibitor is a compound aimed at restoring tumor immunosurveillance. The name of this agent is pembrolizumab.
Phase 2 • Sponsor: Istituti Clinici Scientifici Maugeri SpA • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC